BTG, the specialist pharma company, says it has won approval in the US for its Voraxaze drug.
The drug helps patients who cannot get rid of a chemical called methotrexate from their bodies, usually as a result of impaired kidney function.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
This will be particularly helpful to people undergoing chemotherapy in which methotrexate is used.
Some patients treated with methotrexate develop impaired kidney function, which leads to the accumulation of toxic levels of methotrexate in the blood and puts them at risk of additional toxicity.
Louise Makin, Chief Executive of BTG, commented: "Voraxaze is the first product BTG has taken through to approval in the US and we look forward to its launch over coming months."
The Chief Medical Officer, Guenter R. Janhofer, added "In the clinical trials which led to approval, patients achieved rapid and sustained reductions in plasma methotrexate concentrations."
BTG had a storming 2011, and has gained 43% in the last 12 months.
BS
-
Millions at risk of 'unnecessary' tax bill – how to shield your savingsMillions of Brits could be taxed on their savings interest this year as their savings interest exceeds the personal savings allowance. Are you at risk?
-
Savers will have to wait as long as 48 years to build a £1m cash ISA pot if allowance is cutChancellor Rachel Reeves is rumoured to be planning a cut to the cash ISA allowance in the Autumn Budget, making it harder for savers to build wealth. Will you still be able to build a £1 million cash ISA pot?
